Muscle Atrophy in Sepsis
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Severe sepsis will provoke signals leading to muscle atrophy and weakness. Electrical stimulation will reduce the impact of sepsis.
| Condition |
|---|
|
Atrophy Sepsis Weakness |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Biochemical Pathways to Skeletal Muscle Atrophy in Human Sepsis |
- Electrical stimulation will be associated with upregulation of anabolic signaling molecules and genes, downregulation of catabolic signaling molecules and genes within skeletal muscle of patients with sepsis [ Time Frame: 3 days ] [ Designated as safety issue: No ]
- Electrical stimulation will be associated with improvement of histologic and electrophysiologic and strength parameters within skeletal muscle of patients with sepsis [ Time Frame: 7 days ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Muscle RNA; blood
| Estimated Enrollment: | 25 |
| Study Start Date: | December 2007 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Hypothesis 1: Severe sepsis will be associated with downregulation of anabolic signaling molecules and genes, upregulation of catabolic signaling molecules and genes, and the development of histologic and electrophysiologic abnormalities within skeletal muscle.
Hypothesis 2: Electrical stimulation will improve muscle strength in patients with sepsis.
Hypothesis 3: Electrical stimulation will be associated with upregulation of anabolic signaling molecules and genes, downregulation of catabolic signaling molecules and genes, and improvement of histologic and electrophysiologic parameters within skeletal muscle of patients with sepsis.
Hypothesis 4: The ratio of catabolic:anabolic gene expression on Day 3 will be positively correlated with the severity of clinical weakness on Day 7
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Severe sepsis
Inclusion Criteria:
- Severe sepsis for < 72hr
Contacts and Locations| Contact: Gregory A Schmidt, MD | 3193846746 | gregory-a-schmidt@uiowa.edu |
| United States, Iowa | |
| University of Iowa Hospitals | Recruiting |
| Iowa City, Iowa, United States, 52242 | |
More Information
No publications provided
| Responsible Party: | Gregory A. Schmidt, University of Iowa |
| ClinicalTrials.gov Identifier: | NCT00583206 History of Changes |
| Other Study ID Numbers: | 200706755 |
| Study First Received: | December 20, 2007 |
| Last Updated: | July 22, 2008 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Iowa:
|
sepsis atrophy muscle weakness |
Additional relevant MeSH terms:
|
Asthenia Muscular Atrophy Sepsis Toxemia Atrophy Signs and Symptoms Neuromuscular Manifestations |
Neurologic Manifestations Nervous System Diseases Pathological Conditions, Anatomical Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013